1. Home
  2. BIRK vs TGTX Comparison

BIRK vs TGTX Comparison

Compare BIRK & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Birkenstock Holding plc

BIRK

Birkenstock Holding plc

HOLD

Current Price

$39.42

Market Cap

7.0B

Sector

N/A

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$48.75

Market Cap

7.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BIRK
TGTX
Founded
1774
1993
Country
United Kingdom
United States
Employees
N/A
399
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
7.5B
IPO Year
2023
2008

Fundamental Metrics

Financial Performance
Metric
BIRK
TGTX
Price
$39.42
$48.75
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
14
5
Target Price
$61.43
$49.80
AVG Volume (30 Days)
1.7M
2.3M
Earning Date
05-13-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.17
Revenue
N/A
$2,785,000.00
Revenue This Year
$13.71
$49.08
Revenue Next Year
$14.30
$26.69
P/E Ratio
$17.48
$282.12
Revenue Growth
N/A
N/A
52 Week Low
$31.33
$26.76
52 Week High
$53.53
$59.30

Technical Indicators

Market Signals
Indicator
BIRK
TGTX
Relative Strength Index (RSI) 46.98 41.76
Support Level $37.57 $45.37
Resistance Level $41.89 $58.08
Average True Range (ATR) 1.80 2.11
MACD 0.12 -0.48
Stochastic Oscillator 44.71 29.86

Price Performance

Historical Comparison
BIRK
TGTX

About BIRK Birkenstock Holding plc

Birkenstock is a German footwear brand known for comfort-focused, timeless designs, with 76% of 2022 sales coming from its top five iconic models. Products are made in Europe using sustainable, mostly locally sourced materials. The brand combines orthopedic function with everyday style, appealing to a broad audience. The Americas account for 52% of sales, EMEA 37%, with the remainder coming from Asia-Pacific, which has also the higher future growth expectations.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: